Stay updated with breaking news from Human Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Boehringer Ingelheim announced today that it has launched clinical development of its firstinclass IL11 inhibitor antibody BI 765423 with a Phase 1 study NCT05658107 to assess the safety tolerability and pharmacokinetics in healthy volunteers.
/PRNewswire/ -- Healthy.io, the global leader in transforming the smartphone camera into a medical device, today announced the launch of a program with...
Boehringer Ingelheim and Zealand Pharma AS Nasdaq ZEAL today announced that patients treated with BI 456906 achieved up to 14.9 weight loss after 46 weeks using the planned maintenance dose.
Announced on May 10, 2023, topline results of the phase 2 dose-finding trial for BI 456906 suggests use was associated with reductions in body weight of up to 14.9% during the 46-week study.
Phase II dose-finding trial met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim's cardio-renal-metabolic focus areas Full data will